2013 Fiscal Year Final Research Report
Factors Increasing Interstitial Fibrosis and Its Reduction with Personalized Dosing of Immunosuppressive Drugs after Kidney Transplantation
| Project/Area Number |
23592378
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIURA Maastomo 秋田大学, 医学部, 教授 (30265194)
KOMATSUDA Atsushi 秋田大学, 医学部, 准教授 (70272044)
INOUE Takamitsu 秋田大学, 医学部, 講師 (60375243)
NUMAKURA Kazuyuki 秋田大学, 医学部, 助教 (90566415)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 腎移植 / 移植腎線維増生 / 臨床因子 / 遺伝子多型 / 免疫抑制薬 / カルシニュリン阻害薬 / 個別投与量設計 |
|---|
| Research Abstract |
Patients with CYP3A5*1 allele (CYP3A5 expressers) require a higher daily tacrolimus dose than those with CYP3A5*3/*3 genotype (non-expressers) in order to maintain target trough levels. Recently, we reported that renal cortical interstitial fibrosis (IF) from 0-hour to 1-year post-transplantation increased in non-expressers than CYP3A5 expressers. Therefore, we have started to a personalized initial dosing regimen of tacrolimus based on the CYP3A5 polymorphism. Initial oral doses of tacrolimus were 0.20mg/kg for CYP3A5 expressers and 0.10mg/kg for non-expressers. In the non-personalized regimen, all patients received 0.20mg/kg of tacrolimus.
In results, the personalized medicine of tacrolimus based on the CYP3A5 polymorphism may decrease the pharmacokinetic difference between two groups, and it may contribute better graft function in non-expressers in the early post-transplantation. We are analyzing the 1-year post-transplant outcome and IF.
|
-
-
-
-
[Journal Article] グラセプタのトラフ値はプログラフと同等か?2013
Author(s)
佐藤 滋, 新岡丈典, 加賀谷英彰, 沼倉一幸, 井上高光, 斎藤 満, 小峰直樹, 秋濱 晋, 成田伸太郎, 土谷順彦, 羽渕友則, 三浦昌朋
-
Journal Title
日本臨床腎移植学会雑誌
Volume: 1
Pages: 78-81
Peer Reviewed
-
-
-
-
-
-
-
[Journal Article] Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus2011
Author(s)
Miura Y, Satoh S, Saito M, Numakura K, Inoue T, Obara T, Tsuruta H, Narita S, Horikawa Y, Tsuchiya N, Komatsuda A, Kagaya H, Miura M, Habuchi T
-
Journal Title
Transplantation
Volume: 91
Pages: 78-85
Peer Reviewed
-
-
-
[Presentation] Lack of clinical factors increasing quantitative interstitial fibrosis after renal transplantation under a lower target trough strategy of tacrolimus2013
Author(s)
Komine, N., Satoh, S., Numakura, K., Saito, M., Inoue, T., Narita, S., Miura, Y., Tsuchiya, N., Kagaya, H., Miura, M., Habuchi, H.
Organizer
The 108th Annunal Meeting of the American Urological Association
Place of Presentation
San Diego,USA
Year and Date
20130500
-
[Presentation] Pharmacokinetics and CYP3A5 pharmacogenetics for once- versus twice-daily tacrolimus from first dosing day to 1 year post-transplantation2013
Author(s)
Satoh, S., Niioka, T., Kagaya, H., Numakura, K., Saito, M., Inoue, T., Komine, N., Akihama, S., Narita, S., Tsuchiya, T., Habuchi, T., Miura, M.
Organizer
The 13rd Annunal Meeting of the American Transplant Congress
Place of Presentation
Seattl
Year and Date
20130500
-
-
[Presentation] Personalized initial dose of tacrolimus based on CYP3A5 polymorphism and its impact on 1-month graft function: a preliminary experience2012
Author(s)
Satoh S, Numnakura K, Maita S, Obara T, Inoue T, Narita S, Horikawa Y, Tsuchiya N, Habuchi T, Kagaya H, Miura M.
Organizer
24 th International Congress of the Transplantation Society
Place of Presentation
Berlin
Year and Date
20120700
-
-
-
[Presentation] Basiliximab induction therapy combined with a lower target trough level of tacrolimus and low dose of mycophenolate mofetil decreased interstitial fibrosis at 1-year posttransplantation and improved the 5-year graft survival2011
Author(s)
Satoh S, Numakura K, Saito M, Miura Y, Obara T, Tsuruta H, Inoue T, Narita S, Horikawa Y, Tsuchiya N, Habuchi T, Kagaya H, Miura M
Organizer
The 106th Annual Meeting of the American Urological Association
Place of Presentation
Washington DC
Year and Date
20110500
-
